Literature DB >> 22234804

Spontaneous clearance of primary acute hepatitis C virus infection correlated with high initial viral RNA level and rapid HVR1 evolution.

Lin Liu1, Brian E Fisher, David L Thomas, Andrea L Cox, Stuart C Ray.   

Abstract

UNLABELLED: The aim of this study is to determine whether early viral dynamics and evolution predict outcome of primary acute hepatitis C virus (HCV) infection. HCV- and human immunodeficiency virus-negative injection drug users were enrolled prospectively and followed monthly to identify acute HCV infection using RNA detection. Subjects with more than 1 month between HCV-RNA-negative and -positive visits were excluded to ensure stringent acute infection. Differences in medians of log-transformed viral RNA levels and evolutionary rates in each gene of a 5'-hemigenomic amplicon were assessed using Mann-Whitney's rank-sum test. Correlation coefficient was calculated using Spearman's rank order. Initial viremia level was 50-fold higher in subjects with spontaneous clearance (compared with persistence) of primary acute HCV infection (median, 7.1 versus 5.4 log(10) IU/mL; P = 0.002). Initial viremia level in subjects with interleukin (IL)28B-C allele at rs12979860 and clearance was higher than that in subjects with IL28B-T allele and persistence (P = 0.001). Evolutionary rates in the hypervariable region 1 (HVR1) region of the E2 gene were significantly higher in self-resolvers than those in persistence subjects during early infection, whereas other genes or regions had comparable rates. All major substitutions in HVR1 in persistence subjects were convergent changes, whereas over the same time interval clearance subjects displayed divergent evolution, indicating different immune responses between the two groups.
CONCLUSION: Spontaneous clearance of acute HCV infection is predicted by high initial viremia as well as favorable IL28B genotype and is associated with rapid envelope-sequence evolution. This linkage of host genetics, viral dynamics, and evolution provides new directions for mechanistic studies. (HEPATOLOGY 2012;55:1684-1691).
Copyright © 2012 American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22234804      PMCID: PMC3330174          DOI: 10.1002/hep.25575

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  51 in total

1.  Consensus and ancestral state HIV vaccines.

Authors:  David C Nickle; Mark A Jensen; Geoffrey S Gottlieb; Daniel Shriner; Gerald H Learn; Allen G Rodrigo; James I Mullins
Journal:  Science       Date:  2003-03-07       Impact factor: 47.728

2.  Reversion of CTL escape-variant immunodeficiency viruses in vivo.

Authors:  Thomas C Friedrich; Elizabeth J Dodds; Levi J Yant; Lara Vojnov; Richard Rudersdorf; Candice Cullen; David T Evans; Ronald C Desrosiers; Bianca R Mothé; John Sidney; Alessandro Sette; Kevin Kunstman; Steven Wolinsky; Michael Piatak; Jeffrey Lifson; Austin L Hughes; Nancy Wilson; David H O'Connor; David I Watkins
Journal:  Nat Med       Date:  2004-02-15       Impact factor: 53.440

Review 3.  The interface between innate and adaptive immunity.

Authors:  Kasper Hoebe; Edith Janssen; Bruce Beutler
Journal:  Nat Immunol       Date:  2004-10       Impact factor: 25.606

4.  Displaying the information contents of structural RNA alignments: the structure logos.

Authors:  J Gorodkin; L J Heyer; S Brunak; G D Stormo
Journal:  Comput Appl Biosci       Date:  1997-12

5.  Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection.

Authors:  S A Villano; D Vlahov; K E Nelson; S Cohn; D L Thomas
Journal:  Hepatology       Date:  1999-03       Impact factor: 17.425

6.  Different hepatitis C virus (HCV) RNA load profiles following seroconversion among injecting drug users without correlation with HCV genotype and serum alanine aminotransferase levels.

Authors:  M Beld; M Penning; M McMorrow; J Gorgels; A van den Hoek; J Goudsmit
Journal:  J Clin Microbiol       Date:  1998-04       Impact factor: 5.948

7.  Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein.

Authors:  P Farci; A Shimoda; D Wong; T Cabezon; D De Gioannis; A Strazzera; Y Shimizu; M Shapiro; H J Alter; R H Purcell
Journal:  Proc Natl Acad Sci U S A       Date:  1996-12-24       Impact factor: 11.205

8.  Hepatitis C virus infection in post-transfusion hepatitis. An analysis with first- and second-generation assays.

Authors:  R D Aach; C E Stevens; F B Hollinger; J W Mosley; D A Peterson; P E Taylor; R G Johnson; L H Barbosa; G J Nemo
Journal:  N Engl J Med       Date:  1991-11-07       Impact factor: 91.245

9.  Non-A, non-B posttransfusion hepatitis: comparing C and non-C hepatitis.

Authors:  R L Koretz; M Brezina; A J Polito; S Quan; J Wilber; R Dinello; G Gitnick
Journal:  Hepatology       Date:  1993-03       Impact factor: 17.425

10.  CD8 epitope escape and reversion in acute HCV infection.

Authors:  Joerg Timm; Georg M Lauer; Daniel G Kavanagh; Isabelle Sheridan; Arthur Y Kim; Michaela Lucas; Thillagavathie Pillay; Kei Ouchi; Laura L Reyor; Julian Schulze zur Wiesch; Rajesh T Gandhi; Raymond T Chung; Nina Bhardwaj; Paul Klenerman; Bruce D Walker; Todd M Allen
Journal:  J Exp Med       Date:  2004-12-20       Impact factor: 14.307

View more
  38 in total

1.  Inconsistent temporal patterns of genetic variation of HCV among high-risk subjects may impact inference of transmission networks.

Authors:  Rebecca Rose; Christopher Rodriguez; James Jarad Dollar; Susanna L Lamers; Guido Massaccesi; William Osburn; Stuart C Ray; David L Thomas; Andrea L Cox; Oliver Laeyendecker
Journal:  Infect Genet Evol       Date:  2019-02-22       Impact factor: 3.342

Review 2.  Regulation of hepatic innate immunity by hepatitis C virus.

Authors:  Stacy M Horner; Michael Gale
Journal:  Nat Med       Date:  2013-07       Impact factor: 53.440

3.  Acute Hepatitis C Virus Infection Induces Consistent Changes in Circulating MicroRNAs That Are Associated with Nonlytic Hepatocyte Release.

Authors:  Ramy El-Diwany; Lisa N Wasilewski; Kenneth W Witwer; Justin R Bailey; Kimberly Page; Stuart C Ray; Andrea L Cox; David L Thomas; Ashwin Balagopal
Journal:  J Virol       Date:  2015-07-08       Impact factor: 5.103

4.  Hepatitis C in Punjab--peeping into Pandora's box!

Authors:  Sk Mahiuddin Ahammed; Abhijit Chowdhury
Journal:  Indian J Gastroenterol       Date:  2012-10-20

5.  Interferon lambda 3 genotype predicts hepatitis C virus RNA levels in early acute infection among people who inject drugs: the InC(3) study.

Authors:  Behzad Hajarizadeh; Bart Grady; Kimberly Page; Arthur Y Kim; Barbara H McGovern; Andrea L Cox; Thomas M Rice; Rachel Sacks-Davis; Julie Bruneau; Meghan Morris; Janaki Amin; Janke Schinkel; Tanya Applegate; Lisa Maher; Margaret Hellard; Andrew R Lloyd; Maria Prins; Ronald B Geskus; Gregory J Dore; Jason Grebely
Journal:  J Clin Virol       Date:  2014-09-08       Impact factor: 3.168

6.  Factors associated with hepatitis C virus RNA levels in early chronic infection: the InC3 study.

Authors:  B Hajarizadeh; B Grady; K Page; A Y Kim; B H McGovern; A L Cox; T M Rice; R Sacks-Davis; J Bruneau; M Morris; J Amin; J Schinkel; T Applegate; L Maher; M Hellard; A R Lloyd; M Prins; R B Geskus; G J Dore; J Grebely
Journal:  J Viral Hepat       Date:  2015-01-08       Impact factor: 3.728

Review 7.  The Strange, Expanding World of Animal Hepaciviruses.

Authors:  Alex S Hartlage; John M Cullen; Amit Kapoor
Journal:  Annu Rev Virol       Date:  2016-09-29       Impact factor: 10.431

8.  Plasma interferon-gamma-inducible protein-10 (IP-10) levels during acute hepatitis C virus infection.

Authors:  Jason Grebely; Jordan J Feld; Tanya Applegate; Gail V Matthews; Margaret Hellard; Alana Sherker; Kathy Petoumenos; Geng Zang; Ineke Shaw; Barbara Yeung; Jacob George; Suzy Teutsch; John M Kaldor; Vera Cherepanov; Julie Bruneau; Naglaa H Shoukry; Andrew R Lloyd; Gregory J Dore
Journal:  Hepatology       Date:  2013-05-08       Impact factor: 17.425

Review 9.  Hepatitis C virus: Is it time to say goodbye yet? Perspectives and challenges for the next decade.

Authors:  Heidi Barth
Journal:  World J Hepatol       Date:  2015-04-18

10.  Modeling Combination Hepatitis C Virus Treatment and Prevention Strategies in a Network of People Who Inject Drugs in the United States.

Authors:  Alexei Zelenev; Jianghong Li; Portia Shea; Robert Hecht; Frederick L Altice
Journal:  Clin Infect Dis       Date:  2021-03-01       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.